VCYT Veracyte Inc

Price (delayed)

$23.52

Market cap

$1.72B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.69

Enterprise value

$1.53B

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other ...

Highlights
Veracyte's gross profit has increased by 25% YoY and by 6% QoQ
Veracyte's revenue has increased by 21% YoY and by 4.4% QoQ
The EPS has dropped by 73% since the previous quarter and by 17% year-on-year
Veracyte's net income has shrunk by 72% QoQ and by 16% YoY

Key stats

What are the main financial stats of VCYT
Market
Shares outstanding
73.04M
Market cap
$1.72B
Enterprise value
$1.53B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.62
Price to sales (P/S)
4.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.45
Earnings
Revenue
$343.15M
EBIT
-$49.58M
EBITDA
-$18.21M
Free cash flow
$29.08M
Per share
EPS
-$0.69
Free cash flow per share
$0.4
Book value per share
$14.49
Revenue per share
$4.71
TBVPS
$4.23
Balance sheet
Total assets
$1.12B
Total liabilities
$70.88M
Debt
$13.73M
Equity
$1.05B
Working capital
$213.9M
Liquidity
Debt to equity
0.01
Current ratio
4.74
Quick ratio
4.24
Net debt/EBITDA
10.41
Margins
EBITDA margin
-5.3%
Gross margin
67.8%
Net margin
-14.6%
Operating margin
-16.2%
Efficiency
Return on assets
-4.3%
Return on equity
-4.7%
Return on invested capital
-72.8%
Return on capital employed
-4.6%
Return on sales
-14.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VCYT stock price

How has the Veracyte stock price performed over time
Intraday
-1.05%
1 week
-3.37%
1 month
-13.18%
1 year
-4.43%
YTD
-14.5%
QTD
-14.5%

Financial performance

How have Veracyte's revenue and profit performed over time
Revenue
$343.15M
Gross profit
$232.79M
Operating income
-$55.71M
Net income
-$49.96M
Gross margin
67.8%
Net margin
-14.6%
Veracyte's net income has shrunk by 72% QoQ and by 16% YoY
The operating income has plunged by 66% from the previous quarter and by 16% YoY
The net margin has plunged by 66% from the previous quarter but it has grown by 3.9% YoY
The operating margin has plunged by 59% from the previous quarter but it has grown by 4.1% YoY

Growth

What is Veracyte's growth rate over time

Valuation

What is Veracyte stock price valuation
P/E
N/A
P/B
1.62
P/S
4.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.45
The EPS has dropped by 73% since the previous quarter and by 17% year-on-year
The P/B is 57% below the 5-year quarterly average of 3.8 but 2.5% above the last 4 quarters average of 1.6
The equity has contracted by 2.6% from the previous quarter
The P/S is 56% below the 5-year quarterly average of 11.4 and 4.9% below the last 4 quarters average of 5.3
Veracyte's revenue has increased by 21% YoY and by 4.4% QoQ

Efficiency

How efficient is Veracyte business performance
The company's return on equity has shrunk by 74% QoQ and by 18% YoY
VCYT's return on invested capital has dropped by 72% since the previous quarter and by 5% year-on-year
The ROA has plunged by 72% from the previous quarter and by 16% YoY
The return on sales has dropped by 66% since the previous quarter but it has increased by 8% year-on-year

Dividends

What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCYT.

Financial health

How did Veracyte financials performed over time
The company's quick ratio rose by 17% YoY and by 5% QoQ
The company's current ratio rose by 16% YoY and by 6% QoQ
The debt is 99% less than the equity
VCYT's debt to equity has dropped by 50% year-on-year
The debt has contracted by 18% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.